All In Biotech

Drug Trial Radar · NCT06431607

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

A Phase 2a Randomized, Observer-blind, Dose-finding Study to Evaluate the Immunogenicity and Safety of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 845 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

845

Actual

Start

May 23, 2024

Primary completion

Dec 27, 2024

Study completion Jun 4, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).

Conditions

  • Influenza, Human

Interventions

  • F2G22B/DL001ZBiological

    Study intervention was administered intramuscularly at Day 1.

  • F2H23D/DL001Z-NHBiological

    Study intervention was administered intramuscularly at Day 1.

  • F2H23B/DL001Z-NHBiological

    Study intervention was administered intramuscularly at Day 1.

  • F2H23H/DL001ZBiological

    Study intervention was administered intramuscularly at Day 1.

  • FDQ23A-NH (Flu D-QIV)Combination product

    Control Vaccine was administered intramuscularly at Day 1.

  • GSK5800544ABiological

    Study intervention was administered intramuscularly at Day 1.

  • Flu D-TIVCombination product

    Control Vaccine was administered intramuscularly at Day 1.

  • F2H23A/DL001Z-NHBiological

    Study intervention was administered intramuscularly at Day 1.

  • F2H23G/DL001ZBiological

    Study intervention was administered intramuscularly at Day 1.

  • Fluzone HD QuadrivalentCombination product

    Control vaccine was administered intramuscularly at Day 1.

  • Fluzone HDCombination product

    Control vaccine was administered intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 YA: Geometric Mean Titer (GMT) of Antigen 1 Antibody TiterTime frame: At Day 29
  2. Part 2 YA: GMT of Antigen 1 Antibody TiterTime frame: At Day 29
  3. Part 1 OA: GMT of Antigen 1 Antibody TiterTime frame: At Day 29
  4. Part 2 OA: GMT of Antigen 1 Antibody TiterTime frame: At Day 29
  5. Part 1 YA: Geometric Mean Increase (GMI) of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
  6. Part 2 YA: GMI of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
  7. Part 1 OA: GMI of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
  8. Part 2 OA: GMI of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
  9. Part 1 YA: Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR)Time frame: From Day 1 (baseline) to Day 29
  10. Part 2 YA: Percentage of Participants With Antigen 1 Antibody SCRTime frame: From Day 1 (baseline) to Day 29
  11. Part 1 OA: Percentage of Participants With Antigen 1 Antibody SCRTime frame: From Day 1 (baseline) to Day 29
  12. Part 2 OA: Percentage of Participants With Antigen 1 Antibody SCRTime frame: From Day 1 (baseline) to Day 29
  13. Part 1 YA: Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR)Time frame: At Day 1
  14. Part 2 YA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 1
  15. Part 1 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 1
  16. Part 2 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 1
  17. Part 1 YA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
  18. Part 2 YA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
  19. Part 1 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
  20. Part 2 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Valparaiso, Indiana

  • GSK Investigational Site

    El Dorado, Kansas

  • GSK Investigational Site

    Lenexa, Kansas

  • GSK Investigational Site

    Newton, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Knoxville, Tennessee

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Tomball, Texas

  • GSK Investigational Site

    Newport News, Virginia

  • GSK Investigational Site

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.